Latest Pharmacogenomics News

Get Involved: the Salary Survey is Now Open for Life ScienceHelp The Scientist compile the latest data on salaries within the life-science community. New York, NY (PRWEB) May 25, 2012 The Scientist’s annual Salary Survey is now open to the life science community. With the help of researchers, the magazine provides insights into how salaries from various specialties and fields range in this dynamic industry. Responses are used to compile the most up-...

Genomics in Maternal Child HealthJoin NHGRI June 1 when Barbara Biesecker, Ph.D., NHGRI Social and Behavioral Research Branch, delivers a presentation entitled Genomics in Maternal Child Health. The lecture, which explores the implications of diagnostic prenatal testing, is part of...

Oncobiologics Fills Key Leadership Positions and Names Scientific Advisory BoardCRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts. Stephen J. McAndrew, Ph.D. is now Vice President, Business Development and Vincent J. Benn, Ph.D. has joined the company as Vice President, Clinical & Regulatory Affairs. The company also announced its n...

Study Validating miRview mets2 Published in The Oncologist PHILADELPHIA, PA and REHOVOT, ISRAEL -- (Marketwire) -- 05/25/12 -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that data from studies of miRview® mets² in patients with Cancer of Unknown and Uncertain Primary ("CUP") were published online in The Oncologist in an article titled, "A second generation microR...

Immune self-reactivity triggered by drug-modified HLA-peptide repertoireHuman leukocyte antigens (HLAs) are highly polymorphic proteins that initiate immunity by presenting pathogen-derived peptides to T cells. HLA polymorphisms mostly map to the antigen-binding cleft, thereby diversifying the repertoire of self-derive...

Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae StrainsLA JOLLA, Calif., May 24, 2012 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company commercializing and developing genomic-driven solutions to solve a range of global challenges, today announced they have purchased an 81 acre site for scale up and testing of newly identified and engineered algal strains. The company will use the site, located in the Imperial Valley near the Salt...

Genomind Supports Neuroscience Institute (NEI) with Grant to Further Knowledge of Personalized Medicine Among Health ProfessionalsFunding for New Interactive Learning Module Helps Clinicians Put Pharmacogenomics into Practice. Chalfont, PA (PRWEB) May 24, 2012 Genomind, LLC. has awarded an education grant to the Neuroscience Education Institute (NEI) to further knowledge of personalized medicine among mental health professionals. The Genomind grant will support the development of NEI’s new Mixed Media Activity (MMA) entit...

Blueprint Medicines Welcomes Fidelity Biosciences to Investor SyndicateBlueprint Medicines today announced that new investor Fidelity Biosciences joined existing founding investor Third Rock Ventures in its previously announced $40 million Series A financing. “Blueprint has recruited exceptional talent and created an organization with a real opportunity to transform cancer dr

Nanosmart(R) Pharmaceuticals Welcomes New Vice President Of R&DORANGE COUNTY, Calif., May 24, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, Inc., a California corporation developing a novel drug-delivery platform for cancer pharmaceuticals, announced today that the company has added Dr. Paul Glidden as Vice President of Research and Development. "Dr. Glidden has worked for over 20 years developing new chemical and mole...

Rosetta Genomics to Raise $6.6 Million in Registered Direct Offering PHILADELPHIA, PA and REHOVOT, ISRAEL -- (Marketwire) -- 05/24/12 -- Rosetta Genomics Ltd. ("Rosetta") (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share in a registered direct offering. The offering is e...

Potential To Diagnose Radiation Exposure Using Novel BiomarkersResearchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and tr...

DNA Methylomes And ObesityIn a highlighted paper published online in Nature Communications, researchers from Sichuan Agricultural University and BGI, the world's largest genomics organization, reported the atlas of DNA methylomes in porcine adipose and muscle tissues, providi...

Whole genome sequencing of rare olfactory neuroblastomaThe Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing (WGS) of a rare nasal tract cancer called olfactory neuroblastoma (ONB).

Janssen Healthcare Innovation Announces Discharge Decision Support System (D2S2) Winner of the Janssen Connected Care ChallengeSAN DIEGO, May 23, 2012 /PRNewswire/ -- Janssen Healthcare Innovation, a team within Janssen Research & Development, LLC (Janssen), today announced Discharge Decision Support System (D2S2) is the winner of the crowdsourcing-inspired Janssen Connected Care Challenge and the $100,000 prize. D2S2 is a discharge decision support system that uses a proprietary algorithm to assemble and score...

ECOG Foundation Awards Young Investigators for Research InitiativesYoung researchers affiliated with Indiana University and the University of Pennsylvania. Philadelphia, PA (PRWEB) May 23, 2012 The Eastern Cooperative Oncology Group (ECOG) Research and Education Foundation has announced the recipients of its annual research awards for young investigators. These awards relate to the mission of the foundation to fund scientific research into the causes and treatme...

Cold Spring Harbor Laboratory Joins the Illumina Genome NetworkIllumina, Inc. (NASDAQ:ILMN) today announced that the Cold Spring Harbor Laboratory (CSHL) has joined the Illumina Genome Network (IGN) to provide researchers with broader access to whole genome sequencing (WGS) services. IGN and CSHL will work in collaboration to bring together CSHL’s expertise in molecular biology and cancer genomics with Illumina’s...

PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare ConferenceBOSTON, May 23, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will participate in the Goldman Sachs Healthcare Conference in Ranchos Palos Verdes, California. James Winschel, Sr. Vice President and Chief Financial Officer will present at 4:00 p.m. PT on Wednesday, June 6, 2012. PAREXEL will also be presenting at the Jefferies Healthcare C...

TGen-Scottsdale Healthcare conduct whole genome sequencing of rare olfactory neuroblastoma(The Translational Genomics Research Institute) The Translational Genomics Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have conducted whole genome sequencing of a rare nasal tract cancer called olfactory neurob...

GeneLink Reports First Quarter 2012 Financial ResultsORLANDO, Fla., May 22, 2012 /PRNewswire/ -- GeneLink, Inc. (OTCBB: GNLK.OB, "the Company," or "GeneLink"), a leading consumer genomics biotech company, reports financial results for the three months ended March 31, 2012. Financial Results: On February 10, 2012 the Company closed on the sale of its direct selling subsidiary, GeneWize Life Sciences, Inc., consummating a transaction entered i...

Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global InformationFARMINGTON, Conn., May 22, 2012 /PRNewswire-iReach/ -- Global Information Inc is pleased to announce limited available early bird discounted registration for three significant international healthcare conferences: 2nd Annual World Health Care Congress – Latin America October 29-30, 2012 - Sao Paulo, Brazil – The 2nd Annual World Health Care Congress – Latin America builds on a...

Camargo Appoints K. Gary Barnette as Vice President of Drug DevelopmentCamargo Pharmaceutical Services, an end-to-end drug development service provider specializing in the 505(b)(2) process, has appointed K. Gary Barnette as Vice President of drug development, a key appointment as the company continues to expand. He will be stationed in the Durham, N.C., office.

New York Genome Center Announces Formal Commencement of Collaborative Relationship with IlluminaNew York Genome Center (NYGC) today announced the formal commencement of their collaborative relationship with Illumina, initiated in November 2011, when Illumina was selected as the Center’s lead sequencing technology provider. As a next step in this collaboration, the Center will begin taking delivery of Illumina HiSeq 2000 and 2500 sequencing systems,...

e-Therapeutics preliminary results for the year ended 31 January 2012

22 May 2012- e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its preliminary results for the year ended 31 January 2012. Highlights of 2011/12 (* = events after the 31 January 2012 year end) Drug discovery renewed New wave of work begins using network pharmacology platform Focus on cancer and neurodegenerative diseases Platform ga...

Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical StudiesBOONTON, N.J., May 22, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics today reported positive data from recently completed preclinical studies in rats and dogs for its lead proprietary anorexigenic peptide, UGP281. UGP281, a potent anorexigenic peptide selectively targeting the a...

e-Therapeutics expects first data from new drug trials before yr-endDrug discovery and development company e-Therapeutics (LON:ETX) expects to see the first findings from its new programme of clinical trials before the end of this year.By the end of next year, it should have phase II data on one drug and phase I data...

0 1 2 3 4 ›»

buy Pharmacogenomics market research data and corporate reports now Advertisement